Vaccine Development

Candidate for First Human Hookworm Vaccine Enters Phase 1 Clinical Trial in Brazil

January 19, 2012

WASHINGTON, DC-- Jan. 19, 2012--The Sabin Vaccine Institute (Sabin) today announced the start of a Phase 1 clinical trial of its Na-GST-1 antigen, a candidate for the first human hookworm vaccine. The trial is a major milestone for the vaccine product development partnership (PDP) headquartered at Sabin.

This trial advances Sabin’s goal to develop a safe, efficacious and low-cost vaccine to reduce the global burden of human hookworm, which infects nearly 600 million people worldwide.

Neglected Infections of Poverty Are Found to Be Prevalent in Europe

July 19, 2011

Washington, DC – July 19, 2011 – Neglected tropical diseases (NTDs), which primarily affect poor people in developing countries, are now being found among the poor in relatively affluent regions as well, particularly in parts of Eastern Europe with a history of war and conflict. This is the focus of a new article in the International Journal of Infectious Diseases authored by Dr. Peter Hotez, President of the Sabin Vaccine Institute, and Meredith Gurwith of Georgetown University.

Sabin President Dr. Peter Hotez Announced as Member of The Academy of Medicine, Engineering and Science of Texas

July 1, 2011

The Academy of Medicine, Engineering and Science of Texas (TAMEST) welcomed Sabin President Dr. Peter Hotez as one of its six newest members today.

TAMEST, founded in 2004, brings together Texas’ top scientific, academic and corporate minds to further position the state as a national research leader and to provide broader recognition of the state's top achievers in medicine, engineering and science. Members include Texas Nobel Laureates and more than 240 National Academies members.